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Squamous cell carcinoma of the oesophagus (SCCO) is still a pathology of bad prognosis. Specific therapies are now developed
against epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, c-kit receptor (CD117), vascular
endothelial growth factor (VEGF) and p53 protein. This study was aimed at assessing their expression in a large series of SCCO, as
well as their potential therapeutic interest in this pathology. Immunohistochemical expression of these factors was assessed
retrospectively in 107 cases of SCCO with primary surgery, as well as their relationships to recurrence, metastasis and overall survival
on a long-term follow-up. Human epidermal growth factor receptor 2 and CD117 were expressed in less than 3% of the cases.
Epidermal growth factor receptor and p53 were overexpressed in 68.2 and 66.4% of the cases, and VEGF in 38.3%. Epidermal
growth factor receptor overexpression was significantly related to vascular invasion (P¼0.023). Its diffuse positivity was significantly
related in multivariate analysis to higher local recurrence (P¼0.006) and lower overall survival (P¼0.003), in a subgroup of patients
of poor outcome who had received postoperative adjuvant treatment. These results highlight the great potential prognostic and
therapeutic interest of evaluating EGFR diffuse positivity in locally advanced SCCO.
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Squamous cell carcinoma of the oesophagus (SCCO) still has a bad
prognosis. Improving the survival of SCCO patients is nowadays a
challenge for practitioners confronted with this pathology. Several
options in treatment are available and remain debated among
oncologists, despite the use of standardised surgical procedures
and the development of promising chemotherapy agents such as
Taxans and Irinotecan (Ilson et al, 1999; Metges et al, 2001).
In addition to these drugs, novel therapies are nowadays
developed, specifically directed against growth factor receptors
(Mendelsohn and Baselga, 2000; Gru ¨nwald and Hidalgo, 2003) and
angiogenesis factors (Falm, 2004). These factors are noticeably
interesting targets for therapy, as they seem to be frequently
involved in carcinogenesis pathways. This led us to wonder about
their implication in oesophageal carcinogenesis and potential use
as therapeutic targets in this pathology.
We therefore assessed their immunohistochemical expression in
surgical specimens from SCCO patients within a geographical area
(Brittany, France), where the incidence of this cancer is noticeably
high (Benhamiche et al, 1999), as well as their relationship to
prognosis. Three of the factors studied (epidermal growth factor
receptor (EGFR), human epidermal growth factor receptor 2
(HER-2) and CD117) are tyrosine kinase receptors, defined by an
extracellular ligand-binding specific site, a transmembrane domain
and an intracellular domain with tyrosine-kinase activity. Epider-
mal growth factor receptor and HER-2 belong to the c-erb receptor
family (Downward et al, 1984; Coussens et al, 1985), and are
implicated in cell proliferation, differentiation and migration in
physiological processes. In cancerogenesis, their overexpression
leads to abnormal cell proliferation (Ullrich and Schlessinger,
1990; Klapper et al, 2000; Olayioye et al, 2000). Epidermal growth
factor receptor can be overexpressed through diverse and mainly
post-transcriptional mechanisms. It can be targeted by specific
monoclonal antibodies, for example, IMC-C225 (Mendelsohn and
Baselga, 2000), which is directed against the extracellular domain
of the receptor. Phase-II and phase-III trials with this molecule
have been performed in patients with progressive disease, in
addition to chemotherapy, in refractory colorectal (Saltz et al,
2004), or head and neck (Trigo et al, 2004) cancers. As for HER-2,
it is mostly overexpressed through gene amplification and can be
targeted by a monoclonal antibody, trastuzumab, which has
proved to be quite promising in metastatic breast cancer patients
(Slamon et al, 2001).
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receptor with five extracellular, immunoglobulin-like domains.
This protein is strongly involved in myelopoiesis, melanogenesis
and spermatogenesis (Yarden et al, 1987; Chabot et al, 1988). In
some cancers such as gastro intestinal stromal tumours (GISTs),
point mutations lead to abnormal expression and constitutive
activity of the receptor. CD117 is targeted there by imatimib
mesylate (Heinrich et al, 2002).
Our investigations also focused upon the expression of a growth
factor, vascular endothelial growth factor (VEGF), involved in
physiological and pathological angiogenesis (Connolly et al, 1989;
Ferrara, 2002); it is now targeted by bevacizumab, a humanised
monoclonal antibody (Presta et al, 1997). Phase III randomised
trials have been undertaken; the first results in metastatic
colorectal cancer tend to prove a partial efficiency (Hurwitz
et al, 2004).
We eventually studied the expression of the p53 protein, known
to be mutated in numerous cancers. The mutated p53 protein loses
its ability to regulate cell proliferation (Crawford et al, 1981). New
genetic therapies are presently developed in order to restore the
physiological function of p53 (Edelman et al, 2003).
PATIENTS AND METHODS
Patients included in the study
Our study was conducted retrospectively. We selected patients who
had undergone primary surgery for a SCCO between 1987 and
1997. All of them had been operated on by the same surgeon (PL),
trained in oesophageal surgery. A Lewis-Santy procedure with two-
field lymphadenectomy was used in all cases. Patients who had
received preoperative treatment, those with metastasis at the time
of diagnosis and the ones with other histological types than a SCC
were excluded. We also excluded patients who had died from
postoperative complications and patients with macroscopically or
microscopically incomplete surgical resection. This to a total of
107 patients finally included in the study.
This population was termed ‘SP’ for ‘Study Population’. Survival
analyses were performed in this population. SP patients were also
divided into two groups ‘potþ’( n¼48) and ‘pot ’( n¼59),
depending on whether a postoperative combined radio- and
chemo therapy had been administered or not. Decisions concern-
ing postoperative treatment were made in a multidisciplinary
weekly meeting that included gastroenterologists, oncologists,
surgeons and pathologists. ‘Potþ’ patients consisted of two
groups: those who presented high risk of recurrence and/or
metastasis after surgery, and those receiving radio- and che-
motherapy as treatment for local recurrence and/or metastasis
occurrence. Chemotherapy regimens consisted in an association of
5-fluorouracil (800mgm
 2day
 1, days 1–5) and cisplatin
(15mgm
 2day
 1, days 1–5), whereas the radiotherapy schedule
was a split course regimen with 3gyday
 1, 5 days a week, on weeks
1 and 3. On the opposite, ‘pot ’ patients did not receive any
postoperative adjuvant treatment. This group was mainly com-
posed of patients considered as presenting low risk of local
recurrence or metastasis (pT1, T2 and N0 stages), but it also
included some advanced patients with an altered general condition
that forbade any adjuvant treatment.
Follow-up
Follow-up ended on December 31, 2002. It consisted of medical
history and medical examination with haematological and
biochemical tests, chest radiography, abdominal ultrasonography,
endoscopies with biopsies of surgical anastomosis and CT scan.
Exams were performed every 6 months for the first 2 years, every
year until the fifth year, and then every 2 years, most of the time
for 10 years. For the few patients who were lost to follow-up in
both the Surgical and Oncology Departments, we collected data
from their gastroenterologist, family doctor or from the Cancer
Register Unit.
Immunohistochemical staining methods
For each patient, we retrieved Bouin-fixed and paraffin-embedded
archival tissue samples. Tissue sections (4-mm-thick) were
deparaffinised and rehydrated in water. For antigen retrieval,
samples were incubated 40min at 1001C in a citrate buffer at
pH 6. Endogenous peroxidase activity was blocked for 15min with
0.3% hydrogen peroxide. Then, sections were rinsed with
phosphate-buffered saline (PBS) and incubated with selected
primary antibodies as follows: (i) a polyclonal antibody from
rabbit (Santa Cruz Biotech
s, 1/100 dilution and 45-min incuba-
tion) for VEGF; (ii) polyclonal antibodies against HER-2 (Dako
s,
1/1000 dilution, 30-min incubation) and against CD117 (Dako
s,
1/400 dilution, 20-min incubation); (iii) mouse monoclonal
antibodies against human EGFR (2-18C9 clone, Dako
s, from
Dako EGFR pharmDxt kit K1494 and K1492, 30-min incubation)
and human p53 protein (D0-7 clone, Dako
s, 1/50 dilution, 10-min
incubation). After incubation, all samples were rinsed with PBS.
Those stained with p53, VEGF, HER-2 and CD117 were incubated
with a biotinilised secondary antibody (‘LINK’ from Dako
s for
p53, HER-2 and CD117; Amersham
s for VEGF); the streptavidin–
biotin method was applied for signal detection. Epidermal growth
factor receptor primary antibody was labelled with the diamino-
benzidine (DAB) system after incubation with the secondary
antibody. All slides were then rinsed and counterstained with
haematoxylin.
Staining evaluation
Immunohistochemical staining was assessed by two pathologists
(LG and AV) who worked independently of each other at first, then
reviewed the slides together. For p53 and CD117, a significant
staining of more than 10% of tumour cells was considered as
positive. As done for breast cancer, HER2 staining was evaluated in
a semiquantitative way with a cutoff of 10% ‘3þ’ cells (Penault-
Llorca et al, 2002). Tumour cells were considered to be ‘EGFR
positive’ when their staining was more marked than that of the
adjacent normal epithelium, in agreement with previous inter-
pretations of EGFR in SCCO (Yano et al, 1991; Itakura et al, 1994).
Whenever they had been found positive, we evaluated the
percentage of cells displaying the same intensity of staining.
Staining pattern was qualified as ‘diffuse’ when intensity was alike
in more than 95% of cancer nests, and termed as ‘mosaic’ in the
case of heterogeneous intensity of staining. Vascular endothelial
growth factor staining was considered as positive when more than
30% of tumour cells were stained more intensely than normal
smooth muscle cells, according to a reference interpretation (Inoue
et al, 1997).
Statistical analysis
A w
2-test was carried out to analyse the relationships between the
expression of the studied factors and other clinical parameters.
Survival, local recurrence and metastasis were studied in the study
population ‘SP’, and in ‘potþ’ and ‘pot ’ groups. Patients who
had died from causes other than their oesophageal cancer were
censored for survival analysis. Survival curves were assessed with
the Kaplan–Meier analysis for censored data, and compared with
the log rank test in univariate analysis. The confidence level for
significance was set at Po0.05. A Cox regression model for
multivariate analysis was applied in an ascending step-by-step
method for factors within a significant level of 0.20 in univariate
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s
software (12.0 version).
RESULTS
Characteristics of the studied population
‘SP’ consisted of 94 men and 13 women (sex ratio 7/1). Patients
ranged from 42 to 79 years old. In accordance with the World
Health Organisation Classification standards (Gabbert et al, 2000),
44 patients (41.1%) presented a well-differentiated tumour, 51 a
moderately differentiated one (47.7%) and 12 a poorly differ-
entiated one (11.2%). The depth of invasion, according to TNM
classification (Gabbert et al, 2000), was variable, with a majority of
pT3 stages (n¼61, 57.0%). Vascular invasion and lymph node
involvement were, respectively, observed in 35 (32.7%) and 41
cases (38.3%).
Concerning ‘potþ’ and ‘pot ’ groups, ‘potþ’ patients dis-
played, as suggested by the therapeutic indications, a more locally
advanced disease (higher proportion of pT3 and N1 stages as
compared with the ‘pot ’ group). Outcome variables such as local
recurrence or metastasis occurrence were significantly increased in
this group (P¼0.028 and 0.016, respectively).
Detailed characteristics of SP, ‘potþ’ and ‘pot ’ groups are
summarised in Tables 1 and 2.
Immunohistochemical staining
In all, 73 patients (68.2%) displayed a moderate to intense
expression of EGFR in cancer cells. Immunohistochemical staining
was restricted to cancer cell membranes. A total of 55 tumours
(51.4%) were stained in a ‘mosaic’ pattern and 18 (16.8%) in a
‘diffuse’ one. Nuclear positivity for p53 was found in 71 cases
(66.4%); VEGF was diffusely expressed in 41 cases (38.3%). On the
contrary, HER-2 and CD117 were expressed in only three cases
(2.8%). Human epidermal growth factor receptor 2 staining
intensity was heterogeneous. For CD117, the staining was
cytoplasmic, often faint and focal; all tumours were surrounded
with normal, strongly positive mastocytes (Figure 1).
Relationships with clinical parameters
w
2-tests were conducted in the SP (Table 3). They evidenced a
statistically significant relationship between EGFR expression and
vascular invasion (P¼0.023, data not shown); most of the cases
with vascular invasion displaying EGFR staining, regardless of the
staining pattern. In addition to this, VEGF expression was related
to tumour differentiation (P¼0.012), this factor being rarely
expressed in well-differentiated tumours. Human epidermal
growth factor receptor 2 and CD117 were too rarely expressed to
establish conclusive and statistically significant relationships. A w
2-
test on EGFR, p53 and VEGF expressions found no significant
relationship between them.
Prognosis studies
At the end of follow-up, 84 patients (79.5%) had died, 22 others
(20.6%) were alive and one (0.9%) had been lost to follow-up.
Among the deceased patients, six died from associated throat
cancer, one from lung cancer, nine others from heart failure
(n¼2), haematemesis (n¼1), intestinal infarction (n¼1), inhala-
tion (n¼1), altered condition (n¼1), delirium tremens crisis
(n¼1), suicide (n¼1) and car accident (n¼1). These 16 patients
(15.9%) died from causes that were not directly linked to their
oesophageal cancer or its treatment. They were therefore censored
for survival analysis. Prognosis was not studied for HER-2 or
CD117þ patients: the very low number of involved subjects
invalidated statistical comparisons with the log-rank test. Local
recurrence and metastasis studies were not studied in the ‘pot ’
group for the same reasons.
Survival study
In the SP group, the median survival time was 37 months [18–56].
In univariate analysis, survival was significantly related to pT stage
(P¼0.001), vascular (P¼0.001) and lymph node (Po0.001)
invasion. In multivariate analysis, only pT stage and lymph node
invasion were linked to prognosis (P¼0.027 and 0.007) (Table 4).
Expressions of the factors studied were not significantly linked to
survival in SP.
The ‘pot ’ group demonstrated a median survival time of 82
months [20–144]. Only pT2-T3 stages (P¼0.014), vascular
(P¼0.004) or lymph node invasion (Po0.001) were related to a
reduced survival in univariate analysis. In multivariate analysis
lymph node invasion was associated with a poorer survival
(P¼0.002) (Table 4).
In the ‘potþ’ group, median survival time was 21 months [11–
31]. Patients with advanced pT stage had a significant poorer
survival in multivariate analysis (P¼0.038). For EGFR-expressing
patients, this difference was not found significant in univariate
analysis (P¼0.186). However, patients displaying a ‘diffuse’
expression of EGFR had a significantly reduced survival, both
in univariate (P¼0.006) and multivariate analysis (P¼0.003)
(Table 4).
Table 1 Characteristics of the study population
Clinical parameters and outcome variables Study population
Age
o55 years old 32 (29.9%)
55–65 years old 42 (39.3%)
465 years old 33 (30.8%)
Gender
Male 94 (87.9%)
Female 13 (12.1%)
Tumour differentiation
Well differentiated 44 (41.1%)
Moderately differentiated 51 (47.7%)
Poorly differentiated 12 (11.2%)
pT
pT1 34 (31.8%)
pT2 12 (11.2%)
pT3 61 (57.0%)
pN
N  66 (61.7%)
N+ 41 (38.3%)
Vascular invasion
No 72 (67.3%)
Yes 35 (32.7%)
Local recurrence
No 71 (66.4%)
Yes 36 (33.6%)
Metastasis occurrence
No 56 (52.3%)
Yes 51 (47.7%)
Postoperative treatment
No (pot  group) 59 (55.1%)
Yes (pot+ group) 48 (44.9%)
Total 107 (100%)
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In SP, median recurrence-free survival (RFS) was 108 months. A
significant relationship was established between a reduced RFS and
parietal invasion (P¼0.075), vascular invasion (P¼0.028) and
lymph node involvement (Po0.001) in univariate analysis.
Patients who did not express p53 or who expressed EGFR tended
to have a decreased RFS, but the difference was not significant
(P¼0.073 and 0.079, respectively). In multivariate analysis
(Table 5), only lymph node involvement remained significant
(P¼0.005).
In the ‘potþ’ group, the median RFS was 56 months [23–89].
No clinical or pathological parameter was related to prognosis.
Patients with either EGFR expression or diffuse EGFR expression
had a shorter RFS than the other ones (P¼0.125 and 0.096,
respectively).
In multivariate analysis (Table 5), only EGFR diffuse expression
was significantly related to a shorter RFS, compared to negative
staining for EGFR (P¼0.006).
Metastasis occurrence study
In SP, median metastasis-free survival (MFS) was 46 months [16–
75]. Significant relationships were established between a shorter
MFS and parietal invasion (P¼0.050), vascular invasion
(Po0.001) and lymph node involvement (Po0.001). In the case
of EGFR expression or diffuse EGFR expression, this relationship
was present, but failed to reach statistical significance (P¼0.075
and 0.109). Only lymph node involvement was significant in
multivariate analysis (Po0.001) (Table 5).
In the ‘potþ’ group, median MFS was 17 months [13–20].
Patients with pT2 or pT3 stages had a reduced MFS (P¼0.038), as
well as patients with lymph node involvement (Po0.001), and
patients expressing EGFR in a diffuse pattern (P¼0.016). Patients
expressing EGFR, regardless of the staining pattern, had a shorter
MFS with no statistically significant difference (P¼0.061). In
multivariate analysis, only lymph node involvement was signifi-
cantly related to prognosis (P¼0.004) (Table 5).
DISCUSSION
Originality of our work
Immunohistochemistry is nowadays a simple, reproducible way to
assess the expression of oncogenic factors in paraffin-embedded
samples from cancer tissues. It is therefore more and more used
customarily to study the expression of new potential therapeutic
targets and to determine which patients are the most liable to
answer to these specific therapies.
Table 2 Characteristics of the ‘pot+’ and ‘pot ’ populations
‘Pot ’ group ‘Pot+’ group
Clinical parameters and
outcome variables Nb % (95% CI) Nb % (95% CI) P
Age
o55 years old 18 30.5% [18.8–43.3] 14 29.2% [16.3–42.0] 0.894
55–65 years old 22 37.3% [24.9–44.6] 20 41.6% [27.7–55.6]
465 years old 19 32.2% [20.3–44.1] 14 29.2% [16.3–42.0]
Gender
Male 54 91.5% [84.4–98.6] 40 83.3% [72.8–93.9] 0.197
Female 05 08.5% [02.8–18.7] 08 16.7% [07.5–30.2]
Tumour differentiation
Well differentiated 26 44.1% [31.4–56.7] 18 37.5% [23.8–51.2] 0.777
Moderately differentiated 27 45.7% [33.1–58.5] 24 50.0% [35.9–64.1]
Poorly differentiated 06 10.2% [03.8–20.8] 06 12.5% [04.7–25.3]
pT
pT1 22 37.3% [24.9–49.6] 12 25.0% [12.8–37.3] 0.150
pT2 10 17.0% [08.4–29.0] 05 10.4% [03.5–22.7]
pT3 27 45.7% [33.1–58.5] 31 64.6% [51.1–78.1]
pN
N0 41 69.5% [57.7–81.2] 25 52.1% [38.0–66.2] 0.065
N1 18 30.5% [18.8–42.3] 23 47.9% [33.8–62.0]
Vascular invasion
No 45 76.3% [65.4–87.1] 27 56.2% [42.2–70.3] 0.028
Yes 14 23.7% [12.9–34.6] 21 43.8% [29.7–57.8]
Local recurrence
No 45 76.3% [65.4–87.1] 26 54.2% [40.1–68.3] 0.016
Yes 14 23.7% [12.9–34.6] 22 45.8% [31.7–59.9]
Metastasis
No 45 76.3% [65.4–87.1] 11 22.9% [11.0–34.8] o0.001
Yes 14 23.7% [12.9–34.6] 37 77.1% [65.2–89.0]
Total 59 100% 48 100%
Nb¼number of patients, 95% CI¼95% confidence interval, P¼significance of the difference between ‘pot ’ and ‘pot+’ groups.
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on the simultaneous assessment, in SCCO, of five of the most
interesting molecular targets in oncology and on their relationship
to prognosis. Our series is also quite interesting because of its
homogeneity in therapeutic procedures (primary Lewis-Santy
surgery, similar postoperative treatment in subgroups of patients),
and for its long follow-up (from 5 to 15 years), with only one
patient lost to follow-up.
Indications of postoperative adjuvant treatment in SCCO still
remain controversial. We believe that, among patients with
advanced disease, it can improve disease-free and overall survival.
Several studies support this hypothesis: Bedard and Coll (2001)
demonstrated, in a retrospective study, a significant better survival
in lymph-node positive patients having benefited from post-
operative chemoradiation therapy, as compared to surgery alone.
Ando and Coll multicenter randomized controlled trial (Ando
et al, 2003) also evidenced an improved disease-free survival in
SCCO patients having benefited from adjuvant chemotherapy.
In our study, ‘potþ’ patients, who received postoperative
chemoradiation, had nonetheless a significantly worse prognosis.
However, this worse prognosis was mainly due to the indications
of treatment: as shown in Table 2, these patients had significantly
more often vascular or lymph node invasion and most of them
were treated for local recurrence or metastasis occurrence.
Therefore, this group constituted an interesting collection of
individuals of advanced stages, where the usual prognosis markers
such as lymph node involvement and parietal invasion were not
sufficient to predict prognosis.
Epidermal growth factor receptor in SCCO
Among the factors studied, the EGFR appears to be outstanding in
SCCO. According to literature data, EGFR overexpression in this
pathology ranges from 45.6 to 72.1% (Itakura et al, 1994; Shimada
et al, 1999); our results are consistent with these findings. Most of
the studies found a significant relationship to metastasis
occurrence (Shimada et al, 1999), lymph node involvement and
survival (Yano et al, 1991). By using EGF-binding assays, Ozawa
and Coll (1989) and Mukaida and Coll (1991) drew the same
conclusions, and so did Kitagawa and Coll (1996) from slot-blot
hybridation experiments.
In our work, EGFR expression, evaluated in accordance with
previous standards, was not found significant in prognosis studies,
although the patients expressing EGFR tended to have a poorer
prognosis. However, evaluation of EGFR ‘diffuse’ expression has
revealed particularly interesting, even in a long-term follow-up.
This ‘diffuse’ vs ‘mosaic’ scoring system has rarely been conducted
in SCCO. Yano and Coll (1991) and Itakura and Coll (1994) already
used it in SCCO; more recently, Wilkinson and Coll (2004) also
assessed it in adenocarcinoma of the oesophagus. In our series, it
was found to be significantly related in multivariate analysis to a
worse prognosis in an assortment of patients of advanced stages. It
seemed to be also associated to a reduced recurrence-free survival,
as well as to a reduced metastasis-free survival in univariate
analysis.
As EGFR is also a potential therapeutic target, evaluation of
EGFR overexpression is paramount in cancer strategy. Among the
different molecules against EGFR that have been developed, IMC-
C225, directed against the extracellular domain of the receptor,
inhibits EGFR ligand-binding and autocrine activation and should
be promising in patients overexpressing EGFR. However, in
refractory colorectal cancer, EGFR immunohistochemical over-
expression, with a rate of 1% tumoral positive cells for a positive
score, did not predict response to this therapy (Saltz et al, 2004).
Such a scoring system may not then be entirely relevant, and the
therapeutic implications due to technical procedures (especially in
the assessment of EGFR status before treatment) clearly emphasise
the need for consensus publications. According to our results,
Figure 1 Immunohistochemical expression of carcinogenesis factors in
SCCO: (A) p53 intense nuclear staining, HESx100, (B) EGFR intense
membranous staining, HES 200, (C) VEGF expression: cytoplasmic
staining, more intense in cancer cells ( ) than in smooth muscle cells
(m), HES 200; (D) HER-2 complete and strong membranous staining,
scored ‘3þ’, HES 400; (E) CD117 focal cytoplasmic staining, HES 200.
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the identification of different subgroups of patients liable to be
good candidates for EGFR therapies, especially among patients
with advanced disease. Above all, prospective works assessing
EGFR diffuse expression and its relationship to clinical response to
EGFR-targeted therapies are definitely needed in oesophageal
cancer.
P53 protein in SCCO
Our study evidenced a high expression of p53 in SCCO. This has
been well established in previous studies conducted with nearly the
same immunohistochemical procedures, together with a lack of
correlation to prognosis, which is consistent with our findings
(Sarbia et al, 1994; Hardwick et al, 1997; Shimada et al, 1999; Wang
et al, 1999; Ahn et al, 2002; Rosa et al, 2003). P53 mutations are
Table 3 Expression of the studied factors according to clinical parameters
EGFR expression P53 expression VEGF expression
Clinical parameters
and outcome variables Neg M pos D pos P Neg Pos P Neg Pos P
Age
o 55 yo 10 18 04 0.299 09 23 0.731 15 17 0.091
55–65 yo 10 25 07 15 27 27 15
4 65 yo 14 12 07 12 21 24 09
Gender
Male 33 46 15 0.087 31 63 0.937 59 35 0.752
Female 01 09 03 05 08 07 06
Diff
WD 12 21 11 0.124 18 26 0.126 34 10 0.012
MPD 22 34 07 18 45 32 31
pT
pT1 14 16 04 0.312 09 25 0.284 23 11 0.386
pT2-T3 20 39 14 27 46 43 30
pN
N0 24 33 09 0.196 19 47 0.177 42 24 0.598
N+ 10 22 09 17 24 24 17
Vasc. Inv.
No 28 32 12 0.061 23 49 0.593 48 24 0.128
Yes 06 23 06 13 22 18 17
Local recurrence
No 25 35 11 0.552 20 51 0.092 44 27 0.931
Yes 09 20 07 16 20 22 14
Metastasis occurrence
No 21 28 07 0.278 21 35 0.376 34 22 0.829
Yes 13 27 11 15 36 32 19
EGFR status
Negative 12 22 0.800 21 13 0.268
M pos 17 38 31 24
D pos 07 11 14 04
P53 positivity
Negative 19 17 0.177
Positive 47 24
Total 34 31.8% 55
51.4%1
18 16.8% 36 33.6% 71 66.4% 66 61.7 41 38.3
yo¼years old, Diff¼differenciation, WD¼well differentiated, MPD¼moderately to poorly differentiated, Vasc. Inv.¼vascular invasion, M pos¼mosaic positivity, D
pos¼diffuse positivity, neg¼negative, pos¼positive.
Table 4 Independent prognosis factors in multivariate analysis for overall
survival in SP, ‘pot ’ and ‘pot+’ group
P Odd ratio 95% CI
SP
Parietal invasion 0.027 1.96 1.1–3.6
Lymph node involvement 0.007 2.02 1.2–3.3
Pot 
Lymph node involvement 0.002 3.64 1.6–8.1
Pot+
EGFR ‘mosaic’ positivity 0.535 1.27 0.6–2.7
EGFR ‘diffuse’ positivity 0.003 4.52 1.7–12.2
pT2-T3 invasion 0.038 2.19 1.0–4.6
95% CI¼95% confidence interval.
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speculiarly frequent in high-SCCO incidence areas like Brittany
(Audrezet et al, 1993), where we performed our study; some
geographic specificity might also be implicated. Further studies are
needed to explore the role of p53 in SCCO in these regions, and the
potential impact of p53 activity-restoring therapies.
Vascular endothelial growth factor in SCCO
Vascular endothelial growth factor was overexpressed in about
40% of our cases. In SCCO, its immunohistochemical expression is
variable among studies and ranges from 23.9 (Ogata et al, 2003) to
68.9% (Shimada et al, 1999). Its relationship to prognosis also
remains unclear. Indeed, according to most of the available
studies, VEGF expression significantly predicts a poorer survival
(Inoue et al, 1997; Uchida et al, 1998; Koide et al, 1999, 2001; Kato
et al, 2002). On the contrary, some other recent reports (Ahn et al,
2002; Rosa et al, 2003) are consistent with our results, evidencing a
lack of relationship between VEGF expression and clinical
outcome in SCCO. Underneath this may prevail a difficulty in
immunohistochemical interpretation of VEGF staining. Inoue
et al’s (1997) reference method for staining interpretation seems
to be the most consistent with VEGF overexpression physiopathol-
ogy: VEGF is defined as positive only whenever it is more intensely
expressed in tumour cells than in normal smooth muscle cells.
Only few studies (Ahn et al, 2002; Rosa et al, 2003) used this
method, which permits comparison with our findings. Further
studies about homogeneous groups of patients, with reference
technique and staining interpretation, should cast a precise light
on VEGF implication in oesophageal carcinogenesis and its
potential interest as a therapeutic target. Interestingly, VEGF
expression was significantly related to survival in a previous study
we conducted in a homogeneous population of gastric adenocar-
cinomas (Fondevila et al, 2004), where we applied Inoue’s
interpretation method.
Human epidermal growth factor receptor 2 and CD117
expression
The immunohistochemical evaluation of HER-2 and CD117 is now
quite well standardised. Our follow-up evidenced a very seldom
expression of both HER-2 and CD117 in SCCO. The use of external
or internal positive controls (positive breast cancer for HER-2,
positive mastocytes in the cancer stromal reaction for CD117)
during immunohistochemical procedures rules out the hypothesis
of false-negative reactions.
For HER-2, these results are consistent with other studies (Shiga
and Coll, 1993), but we lack of comparative data since, to our
knowledge, studies concerning HER-2 or CD117 expressions are
very scarce. According to our findings, these factors nevertheless
appear to be of poor interest as potential therapeutic targets in
SCCO.
CONCLUSIONS
Understanding of biological processes implicated in carcinogenesis
is a new asset in the treatment of cancer. In Brest University
Hospital, a multidisciplinary team made up of oncologists,
gastroenterologists, surgeons and pathologists has grown for
several years very concerned about oesophageal cancer. Our wide
series of SCCO patients granted us enough material to conduct a
retrospective study of 107 patients, with particularly long follow-
up (from 5 to 15 years), and only one patient lost to follow-up.
This was the ideal medium to assess simultaneously the expression
of five major molecular targets in cancerology, as well as their
relationship to prognosis.
We could therefore demonstrate that EGFR diffuse expression,
in a subgroup of patients with more advanced disease, was
significantly related to a lower overall survival and higher local
recurrence in multivariate analysis. On the contrary, p53 protein
and VEGF were overexpressed in our series, but not related to
prognosis. As for HER-2 and c-kit receptor, they were very rarely
expressed.
Epidermal growth factor receptor would therefore be a good
potential target for specific therapies, especially those directed
against the extracellular domain of the receptor, such as IMC-
C225. There is still controversy about the relevance of EGFR
scoring in selecting patients for EGFR-directed therapies. How-
ever, evaluation of EGFR ‘diffuse’ vs ‘heterogeneous’ expression
has seldom been performed, and has never been related to clinical
response to EGFR-targeted therapies in SCCO. Further prospective
works and clinical trials concerning EGFR-directed therapies,
assessing EGFR diffuse positivity, are needed. If they confirmed
our results, they would bring new hopes in the clinical outcome of
SCCO.
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